Shareholders of Verona Pharma agree to Merck’s acquisition proposal

Verona Pharma submitted a Proxy Statement to the Securities and Exchange Commission on August 18, 2025, outlining the details of a Court Meeting and the voting results. The Proxy Statement provided important information to shareholders regarding various matters affecting the company.

During the Court Meeting, shareholders had the opportunity to vote on key decisions that would impact Verona Pharma’s future. The voting results revealed the shareholders’ stance on important issues and helped in determining the direction the company would take moving forward.

The Proxy Statement was a crucial document that outlined the voting process and ensured that shareholders were well-informed about the decisions being made. By providing transparency and clarity, the Proxy Statement allowed shareholders to actively participate in the decision-making process and have their voices heard.

The Proxy Statement served as a formal communication channel between the company and its shareholders. It provided detailed information about the matters at hand, enabling shareholders to make informed decisions that aligned with their interests and values. The Proxy Statement played a vital role in ensuring accountability and promoting good governance within the company.

Overall, the Proxy Statement presented by Verona Pharma to the Securities and Exchange Commission on August 18, 2025, was a crucial document that informed shareholders about the results of the Court Meeting and the voting outcomes. It served as a transparent and informative tool that allowed shareholders to participate in important decisions that would shape the future of the company. By providing clarity and openness, the Proxy Statement helped to foster trust and accountability within the company and among its shareholders.